Carfilzomib-associated renal toxicity is common and unpredictable: a comprehensive analysis of 114 multiple myeloma patients

Carfilzomib (CFZ) is a non-reversible proteasome inhibitor approved for the treatment of patients with relapsed and refractory myeloma (RRMM). Its use has been associated with cardiovascular toxicity but although recently a signal of clinically significant renal complications has also been identifie...

Descripción completa

Detalles Bibliográficos
Autores principales: Fotiou, Despina, Roussou, Maria, Gakiopoulou, Charikleia, Psimenou, Erasmia, Gavriatopoulou, Maria, Migkou, Magdalini, Kanellias, Nikolaos, Dialoupi, Ioanna, Eleutherakis-Papaiakovou, Evangelos, Giannouli, Stavroula, Delavinia, Christina, Efstathiou, Kostantinos, Kontogiannis, Sofoklis, Terpos, Evangelos, Dimopoulos, Meletios A., Kastritis, Efstathios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7642386/
https://www.ncbi.nlm.nih.gov/pubmed/33149167
http://dx.doi.org/10.1038/s41408-020-00381-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7642386/
https://www.ncbi.nlm.nih.gov/pubmed/33149167
http://dx.doi.org/10.1038/s41408-020-00381-4

Ejemplares similares